Rezera Delays IPO Due to Market Conditions Ahead of Announced Trading Start

Key Facts

Rezera postponed its IPO on the evening of Wednesday, November 11, 2026, due to market conditions, according to IPO Scoop, meaning the start of trading in its shares the following day was not confirmed. The company’s amended filing with the U.S. Securities and Exchange Commission still described an IPO contingent on completion and listing the shares on the Nasdaq Global Market. Accordingly, the step that would allow investors to trade the stock remained tied to closing the offering and meeting the listing condition set out in the prospectus. The prospectus indicated an offering of 16,666,667 shares, with an expected price range of between 11 and 13 dollars per share. The available offering record did not confirm that these conditions had been met after the postponement.

The proposed price range would have valued the offering based on the number of shares offered and their expected price, but the prospectus did not present it as a completed transaction: it described the price as expected and made listing a condition of completion. An affiliate of GSK also expressed interest in purchasing up to 2,083,333 shares, for up to 25 million dollars at an assumed price of 12 dollars per share. The prospectus said this interest was nonbinding, so it did not represent a confirmed purchase or guaranteed proceeds for the company. The assumed price is at the midpoint of the announced offering range, while the size of the proposed participation remains subject to completion of the offering and the decision of the entity concerned. This indication does not change the conditional nature of the offering described in the company’s prospectus.

Rezera is a clinical-stage biotechnology company that says it is developing oral inhibitors of the inflammation-related NLRP3 pathway. Ruvonoflast is its lead candidate, and the company says it has undergone five completed clinical trials in humans, in which it was well tolerated. In a separate announcement about the RESOLVE-1 trial, the company said the study included 176 participants, who were randomly assigned to receive a daily dose of 150 or 300 mg of ruvonoflast or a placebo, alongside standard care. Treatment lasted 24 weeks, and the trial included participants with and without type 2 diabetes. The company also said the candidate’s clinical dataset includes more than 400 participants across five trials lasting up to nine months.

The company cited an earlier study in which it said hsCRP levels fell 82% after four weeks among participants with elevated cardiovascular risk and a high inflammatory burden. This result was included in the company’s overview of the candidate’s development background, alongside trial data underpinning its next steps. Rezera, meanwhile, reported a net loss of 42.179 million dollars in 2025, compared with a loss of 25.205 million dollars in 2024, according to the offering prospectus. The comparison shows an increase in losses between the two fiscal years cited, as the company continues to develop its clinical candidates and outline future plans for the offering. The prospectus did not present completion of the offering as a done deal, but linked the listing to completion of the transaction.

The company says it plans to start a Phase 3 trial of ruvonoflast in the first half of 2027, targeting a results readout in 2028 and the filing of a new drug application in early 2029. These are the company’s planned timelines for developing the candidate; starting the trial, obtaining its results and filing the application remain subsequent steps. In parallel, Rezera expects to announce topline results from the Phase 1 trial of its candidate trabzanoflast in the fourth quarter of 2026. This puts results for the second candidate among the near-term developments identified by the company, while the subsequent stages for ruvonoflast extend into later years. The timing of Rezera’s offering and share listing, however, has not been confirmed by the available sources following the postponement on the evening of November 11 due to market conditions.